Antitumor activity of oxaliplatin, 5-FU and paclitaxel given alone and in combination with ZD1839 in human gastric carcinoma cells in vitro.

  • Jang, Ji-Hyun (Catholic Research Institutes of Medical Science, The Catholic Univ of Korea) ;
  • Lee, Sang-Hak (Catholic Research Institutes of Medical Science, The Catholic Univ of Korea) ;
  • Kang, Jin-Hyoung (Catholic Research Institutes of Medical Science, The Catholic Univ of Korea) ;
  • Sun, Hee-Sik (The Catholic Univ of Korea) ;
  • Kuh, Hyo-Jeong (Catholic Research Institutes of Medical Science, The Catholic Univ of Korea)
  • Published : 2002.10.01

Abstract

ZD1839 is a new anticancer agent which selectively inhibits EGFR tyrosine kinase. Oxaliplatin (LOHP), 5-FU (FU), and paclitaxel (PTX) have shown to be highly active against the gastric carcinomas. and ZD1839 is considered as a good candidate for the treatment of gastric cancers when combined with cytotoxic agents. In this study, we evaluated the antitumor effects of these agents in SNU-l human gastric cancer cells either alone or when given as a doublet. (omitted)

Keywords